Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $11.30 Analyst target: $21.00 Upside: 85.84%
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.